CHMP positive on new label extensions
This article was originally published in Scrip
Executive Summary
The CHMP has recommended expanding the labels of four drugs: Lilly's Adcirca (tadalafil), The Medicines Company's Angiox (bivalirudin), Lilly's Cymbalta (duloxetine) and Boehringer Ingelheim's Xeristar (duloxetine).